FLUOXETINE WITHDRAWAL SYMPTOMS / HELP WEANING OFF FLUOXETINE NATURALLY
Fluoxetine was launched under the trade name Prozac in 1987 and has the longest half life (time it takes to leave the body) of any antidepressant - taking about 30 days - this often causes a delay on the onset of Fluoxetine withdrawal symptoms.  Common side effects of Fluoxetine are nausea, headache, sexual dysfunction, insomnia, anxiety, dizziness and weight gain or loss. Multiple studies have calculated that 56% of antidepressant users experience withdrawal symptoms. Dependence to Fluoxetine places extreme demands on your body and nervous system. Point of Return implements slow reduction schedules and specifically designed nutraceuticals to support the body's unique needs while weaning off Fluoxetine during a Fluoxetine taper. Let our experts guide you on the correct taper rates, we have helped people all over the world and are here to help you too.* 
Below is information about Fluoxetine, Fluoxetine withdrawal, and how to stop taking Fluoxetine naturally.
SUCCESSFUL CHOICES YOU CAN MAKE RIGHT NOW
LEARN MORE ABOUT OUR IN-HOME WITHDRAWAL PROGRAM
TALK TO A REAL PERSON 866-605-2333 (toll-free)
WHAT IS FLUOXETINE WITHDRAWAL LIKE?
The debt of gratitude I owe you is something I can never repay. My family and I will be forever grateful.by Rachel Antidepressant Withdrawal Success
FLUOXETINE WITHDRAWAL HELP - WEANING OFF FLUOXETINE NATURALLY
Our Fluoxetine At-Home Withdrawal Tapering Program combines a slow Fluoxetine taper with a powerful holistic approach to minimizing symptoms. This allows you to wean off Fluoxetine gently under the guidance of Our Team, Your Physician, and Pharmacist. Our Pre-taper is necessary to help provide relief. You do not taper Fluoxetine until you are feeling better. Our nonprofit has been helping people all over the world to escape Fluoxetine and antidepressants dependence for over 17 years. You are not alone through the process.* *
Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our innovative approach to antidepressant tapering encompasses a holistic method to empower you on your path to recovery. Don't wean Fluoxetine alone, work with our Prescription Drug Experts.*
FLUOXETINE WITHDRAWAL SYMPTOMS MAY INCLUDE*
- severe headache
- burning or tingling sensations around the body
- brain zaps / brain shivers
- rushing noise in the head
- concentration problem
- reduced appetite
- excessive dreaming
- gastrointestinal issues 
I will forever be grateful for your help, and I continue to tell others about your marvelous program of drug recovery when the opportunity presents itself. I will never forget you and your compassion toward me and so many others.by Tom Antidepressant Withdrawal Success
IMAGINE BEING FREE OF FLUOXETINE DEPENDENCY
✔ Proven Program completed At-Home
✔ Slowly Stop Taking Fluoxetine
✔ All-Natural Nutraceuticals to help ease symptoms and make Fluoxetine Withdrawal more comfortable*
✔ Professional information and support to empower you
✔ Free Mentoring on our 24/7 private Discussion Board
Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program (USA & Canada Only)
FLUOXETINE WITHDRAWAL TIMELINE
It is estimated that 56% of people quitting antidepressants will experience withdrawal symptoms. Fluoxetine, like all antidepressants, work by altering our natural neurotransmitter production, often shunting Serotonin levels higher in the brain while starving other areas of the body. Fluoxetine withdrawal can materialize within a few days or weeks of a dose reduction (due to the long half life) and is too often mistaken for depression. The physical complaints are also too often not attributed to the Fluoxetine withdrawal. Weaning off Fluoxetine slowly is necessary to minimize the Fluoxetine withdrawal symptoms. Generally the first symptoms are felt after either missing a dose or reducing a dosage. For some the Fluoxetine withdrawal symptoms are severe, immediately interfering with life, and for others the symptoms are more tolerable. If you want help to safely taper Fluoxetine, please contact our experts.*
FLUOXETINE WITHDRAWAL SUCCESS STORIES
I Thank you Point of Return for all of your patience and kindness. We in a fragile state need your extra kindness. Thank you for all you have done for me and my roach to recovery. More...
Betty (Fluoxetine Withdrawal Success Story)
I also need to thank the whole Point of Return staff. I called many times looking for help and always got an uplifting word or laugh. For those currently struggling, try their withdrawal program. Give the Point of Return team a call or email. More...
Eric (Fluoxetine Withdrawal Success Story)
I have found that if you work the Point of Return program that it will work for you. The results are there if you do your part and work the program. I strongly recommend Point of Return to others. More...
Rachel (Fluoxetine Withdrawal Success Story)
Fluoxetine (Prozac) targets Serotonin, the neurotransmitter found primarily in the gastrointestinal tract, blood platelets and central nervous system, and is thought to contribute to feelings of happiness. Serotonin is critical in the regulation of mood, appetite and sleep patterns, but also used in memory and learning. The widespread function of Serotonin helps to explain the extensive list of side effects and the Prozac Discontinuation Syndrome (withdrawal). Fluoxetine (Prozac) has the longest half-life of any antidepressant, meaning it stays in the body for an extended period of time. Many patients do not realize they are in withdrawal as the symptoms may appear weeks after stopping the drug. A gradual taper is recommended. Contact Us if you need help tapering off of Fluoxetine or have questions.
Prozac (Fluoxetine) failed in clinical trials as an antihypertensive medication and again as an obesity drug. While it did not show improvement for patients hospitalized as psychotic and actually made some patients worse, Prozac found its home as an antidepressant after it improved the mood of five mildly depressed volunteers. It was then launched as an antidepressant in 1988 and was responsible for more than one-quarter of Eli Lilly Pharmaceutical’s income. The marketing strategy of providing a cure for an illness was born by Interbrand, the world’s leading branding company (Microsoft, Nikon, Nintendo, Sony) and the name Prozac was chosen because it was short and had a positive and professional sound. Lilly printed 8 million brochures highlighting the symptoms of depression with a treatment option and patients began asking for the drug by name. It was the success of Prozac that created the market with similar antidepressants called SSRIs (Selective Serotonin-Reuptake Inhibitors).
Prozac (Fluoxetine) erased the stigma of depression but brought with it a movement to advertise depression and provide drugs to treat it. In 2001 Prozac lost its patent protection and Eli Lilly lost $35 million of its market value as generic versions were released.
Prescriptions for Fluoxetine have increased 23% for children under the age of two. U.S. Experts warn that the steep rise comes in spite of no published research investigating the effectiveness and potential health risks for young children.
Fluoxetine (Prozac)has the longest half-life of any antidepressant, meaning it stays in the body for an extended period of time. Many patients do not realize they are in withdrawal as the symptoms may appear weeks after stopping the drug.
FLUOXETINE SIDE EFFECTS AND ADVERSE REACTIONS
FLUOXETINE ADVERSE REACTIONS MAY INCLUDE: per PDR
Severe: visual impairment, tardive dyskinesia, suicidal ideation, arrhythmia exacerbation, heart failure, myocardial infarction, proteinuria, seizures, peptic ulcer, hematemesis, GI bleeding, pancreatitis, cholecystitis, esophageal ulceration, GI obstruction, muscle paralysis, pulmonary hypertension, thrombosis, ventricular fibrillation, coronary vasospasm, stroke, atrial fibrillation, cardiac arrest, bradycardia, pneumothorax, apnea, pulmonary edema, laryngeal edema, ocular hypertension, hearing loss, oliguria, diabetic ketoacidosis, hyperkalemia, torticollis, thrombotic thrombocytopenic purpura (TTP, aplastic anemia, hemolytic anemia, SIADH, torsade de pointes, ventricular tachycardia, erythema nodosum, pulmonary fibrosis, lupus-like symptoms, bronchospasm, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, anaphylactoid reactions, angioedema, serum sickness, vasculitis,Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), laryngospasm, toxic epidermal necrolysis, eosinophilic pneumonia, pulmonary embolism, optic neuritis, hepatic failure, hepatic necrosis, renal failure (unspecified), bone fractures, serotonin syndrome, persistent pulmonary hypertension of the newborn, neonatal abstinence syndrome
Moderate: impotence (erectile dysfunction), ejaculation dysfunction, constipation, oral ulceration, melena, esophagitis, cholelithiasis, dysphagia, glossitis, gastritis, colitis, stomatitis, neuropathic pain, myoclonia, teeth grinding (bruxism), migraine, akathisia, ataxia, hypertonia, hostility, psychosis, euphoria, depression, anemia, hypotension, angina, orthostatic hypotension, peripheral edema, edema, vaginal bleeding, atopic dermatitis, skin ulcer, photophobia, conjunctivitis, elevated hepatic enzymes, urinary incontinence, dysuria, hematuria, urinary retention, cystitis, hypothyroidism, hypercholesterolemia, dehydration, hypokalemia, hyperlipidemia, gout, bone pain, synovitis, mania, abdominal pain, fecal incontinence, neuritis, hallucinations, EEG changes, dysarthria, hyperesthesia, dystonic reaction, lymphocytosis, thrombocytopenia, leukopenia, phlebitis, priapism, psoriasis, furunculosis, hypoxia, hypoventilation, hemoptysis, blepharitis, iritis, exophthalmos, hyperacusis, hepatitis, flank pain, glycosuria, hyperglycemia, diabetes mellitus, hypocalcemia, hyperuricemia, myopathy, myasthenia, osteoporosis, confusion, amnesia, QT prolongation, hypertension, palpitations, chest pain (unspecified), dyskinesia, memory impairment, impulse control symptoms, hematoma, bleeding, platelet dysfunction, hyponatremia, galactorrhea, hyperprolactinemia, dyspnea, cataracts, jaundice, hypoglycemia, osteopenia, withdrawal, growth inhibition
Mild: insomnia, nausea, headache, asthenia, diarrhea, anorexia, drowsiness, anxiety, tremor, xerostomia, yawning, libido decrease, dyspepsia, pharyngitis, dizziness, hyperhidrosis, urticaria, rash, sinusitis, abnormal dreams, flushing, flatulence, vomiting, pruritus, weight loss, epistaxis, fever, hypersalivation, polydipsia, eructation, paranoia, vertigo, hypoesthesia, ecchymosis, syncope, breast enlargement, orgasm dysfunction, mastalgia, menorrhagia, libido increase, breast discharge, amenorrhea, leukorrhea, photosensitivity, alopecia, maculopapular rash, skin discoloration, acne vulgaris, malaise, hyperventilation, hiccups, mydriasis, xerophthalmia, polyuria, urinary urgency, nocturia, pelvic pain, arthralgia, muscle cramps, paresthesias, hyporeflexia, petechiae, purpura, pallor, hirsutism, seborrhea, parosmia, diplopia, appetite stimulation, weight gain, dysgeusia, emotional lability, hyperkinesis, agitation, hypothermia, chills, otalgia, tinnitus, increased urinary frequency, gynecomastia, influenza
FLUOXETINE BOXED WARNINGS: per PDR:
Children, growth inhibition, suicidal ideation
Fluoxetine is approved for the treatment of depression in children 8 years of age and older, and for the treatment of obsessive-compulsive disorder (OCD) in children 7 years of age and older. The safety and effectiveness of fluoxetine in younger children have not been established. In October 2004, the FDA directed manufacturers of all antidepressants to include a boxed warning detailing the risk of suicide in pediatric patients. A causal role has been established for antidepressants in inducing suicidality in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n=4400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants (SSRIs and others). The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with SSRIs and other antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in children or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or at the time of dose increase or decrease. It is unknown if the suicidality risk in children and young adults extends to longer-term therapy (i.e., beyond several months). The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment are considered at an increased risk for suicidal ideation or attempts, and should be closely monitored during treatment with fluoxetine. In patients who exhibit changes in symptoms, worsening of depression or emergent suicidality, a decision should be made to change or discontinue treatment. If discontinuing, medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose. The potential for growth inhibition in pediatric patients should be monitored during SSRI therapy. Monitor height and weight periodically while the patient is receiving fluoxetine. Data are inadequate to determine whether the chronic use of SSRIs causes long-term growth inhibition; however, decreased weight gain has been observed in children and adolescents receiving fluoxetine.
FLUOXETINE TECHNICAL DATA AND REFERENCES
According to the FDA:
Discontinuation of Treatment
Patients should be advised to take PROZAC exactly as prescribed, and to continue taking PROZAC as prescribed even after their symptoms improve. Patients should be advised that they should not alter their dosing regimen, or stop taking PROZAC without consulting their physician [see Warnings and Precautions (5.15)]. Patients should be advised to consult with their healthcare provider if their symptoms do not improve with PROZAC.
If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see Warnings and Precautions
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized with Your physician to help you with your drug withdrawal process and with his or her consent throughout.
*This program is not meant to cure or prevent any disease or illness.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..